Skip to content
Search

Latest Stories

COVID-19 Inquiry: RPS calls for greater recognition and support for pharmacists

COVID-19 Inquiry: RPS calls for greater recognition and support for pharmacists

Despite their crucial role during the pandemic, community pharmacy was often an afterthought in government planning, guidance and communications - RPS tells COVID-19 Inquiry

The Royal Pharmaceutical Society (RPS) presented key evidence to the UK COVID-19 Inquiry on 10 September, underscoring the vital role of pharmacists and pharmacy teams during the pandemic.

Deirdre Domingo, legal representative for the RPS, delivered the statement during the Module 3 public hearings, which focus on the impact of COVID-19 on healthcare systems across the UK.


As the professional body representing pharmacists and pharmaceutical scientists in Great Britain, the RPS urged the Inquiry to consider several critical issues:

  • Recognition of pharmacists as key workers

The RPS highlighted the crucial role pharmacy teams played in ensuring continued access to essential medicines and their integral involvement in the roll-out of COVID-19 and flu vaccinations.

However, the Society also raised concerns over significant failures and challenges, such as inadequate safety measures to protect pharmacists at work, confusing national guidance, increased hostility towards healthcare professionals, and a disparity in the treatment of community pharmacy compared to NHS staff.

“Despite their crucial role providing care throughout the pandemic, the pharmacy profession, and particularly community pharmacy, was often an afterthought in government planning, guidance and communications, and this had a hugely detrimental impact on their morale and wellbeing,” the RPS statement reads.

  • Pharmacy service resilience in future health emergency  

The RPS highlighted how pharmacy teams went above and beyond to support patient care during the pandemic.

But it also warned of growing pressures on community pharmacies, which are leading to closures and reduced access to care, especially in deprived and rural areas.

“The pharmacy workforce is currently in a perilous state,” the RPS noting that there’s “an increase in vacancies and staff shortages across the sector.”

  • Impact of medicine shortages on patient care

The pandemic exposed the complexity of the global medicines supply chain, causing shortages of many commonly used drugs, such as paracetamol, as well as those used in critical care.

The RPS stressed that it has become increasingly common to see medicines shortages within “fragile” supply chains.

  • Investment in and resilience of aseptic pharmacy services

Another key issue that the RPS is seeking the Inquiry to consider is “whether there is adequate investment and resilience in aseptic pharmacy services” in the event of a future pandemic.

The Inquiry was urged to assess the resilience of medication supply and pharmacy services across all care settings, particularly the current investment and planning in the medicines supply chain and production facilities.

  • The welfare of pharmacy teams

The Society highlighted the importance of equitable access to health and wellbeing support for all health professionals providing NHS services across care settings.

This includes Infection, Prevention and Control (IPC) guidance, and the provision of personal protective equipment (PPE).

The RPS also emphasised the importance of early engagement with pharmacy stakeholders in the event of future pandemics, particularly concerning medicines delivery services and roll-out of a mass vaccination programmes.

The RPS urged the Inquiry to recognise the critical role of pharmacists across all sectors in responding to the pandemic and to address the significant challenges they faced to improve future preparedness and resilience in the health system.

RPS President Claire Anderson stressed the importance of reflecting on past challenges to build a more resilient NHS for the future.

“Pharmacists and pharmacy teams across the whole of the health service played a crucial role during COVID-19, supporting patient access to care and maintaining vital access to medicines.

“Our evidence has reflected how pharmacy teams went above and beyond in the face of unprecedented demand and the most challenging of circumstances.

“I hope our members’ experiences that we have shared will continue to help shape and inform the Inquiry’s conclusions.

“With continued pressures on the health service and the whole of the workforce, it is more important than ever to learn from the past so we can build a more resilient NHS and help prepare for the future.”

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less